Evidence map›Paper›PMID 22583147›Full record

ReviewAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2012

Epidemiology and management of hypertension in the Hispanic population: a review of the available literature.

Nicolas J Guzman

Open access · bronzeAbstract readReview
In one paragraph

Review in American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 38 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. A Cyclical Model of Barriers to Healthcare for the Hispanic/Latinx Population.Journal of racial and ethnic health disparities · 2024
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Predictors for Blood Pressure Reduction in American Latinos: Secondary Analysis of the Adelgaza Program Data.Hispanic health care international : the official journal of the National Association of Hispanic Nurses · 2020
    Article
  13. Article
  14. "Contemporary clinical trials communications · 2019
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Identification of Barriers to Stroke Awareness and Risk Factor Management Unique to Hispanics.International journal of environmental research and public health · 2015
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Nicolas J GuzmanThe George Washington University Medical Faculty Associates, Division of Renal Diseases and Hypertension, Washington, DC 20037, USA. nguzman@mfa.gwu.edu
GW Medical Faculty Associates · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hispanics are the fastest growing ethnic minority in the USA. Among Hispanics, lack of hypertension awareness and lack of effective blood pressure (BP) control are problematic, as are higher incidence rates of hypertension-related co-morbidities compared with non-Hispanic populations. Moreover, there are currently no hypertension treatment guidelines that address the unique characteristics of this ethnic group. This article discusses ethnic differences in hypertension and cardiovascular risk factors and reviews the literature on the efficacy of antihypertensive agents in Hispanic patients, with a focus on the role of renin-angiotensin-aldosterone system (RAAS) inhibition in the management of hypertension in these patients. Hypertension in Hispanic patients can be challenging to manage, in part because this population has a higher prevalence of obesity, diabetes, and metabolic syndrome compared with non-Hispanic whites. The presence of these co-morbidities suggests that RAAS-inhibitor-based therapies may be particularly beneficial in this population. However, few studies have evaluated the efficacy of antihypertensive treatments in Hispanic patients. Two outcomes studies in hypertensive patients have shown the benefits of treating Hispanic patients with antihypertensive therapy and included RAAS inhibitors as part of the treatment regimen. In addition, BP-lowering trials have shown the antihypertensive efficacy of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors, although data on the latter are more limited. Additional studies are needed to more thoroughly evaluate the effects of RAAS inhibitors (and other drug classes) on outcomes and BP lowering in the Hispanic hypertensive population.

Indexed as

Antihypertensive AgentsBlood PressureHealth Knowledge, Attitudes, PracticeHispanic or LatinoHumansHypertensionOutcome Assessment, Health CarePractice Guidelines as TopicRenin-Angiotensin SystemRisk FactorsUnited StatesAntihypertensive Agents

Identifiers

PMID22583147
PMCPMC3624012
OpenAlexW2041848287

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.